Patent: 10,562,956
✉ Email this page to a colleague
Summary for Patent: 10,562,956
| Title: | Recombinant fibrinogen |
| Abstract: | The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system. |
| Inventor(s): | Abraham Bout, Joseph Grimbergen, Jacob Koopman |
| Assignee: | Mallinckrodt Pharma IP Trading DAC |
| Application Number: | US15/331,942 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,562,956
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Pharma Ip Trading Dac | RAPLIXA | fibrin sealant (human) | Powder | 125523 | April 30, 2015 | ⤷ Get Started Free | 2036-10-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,562,956
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2010004004 | ⤷ Get Started Free |
| United States of America | 2017037108 | ⤷ Get Started Free |
| United States of America | 2011177524 | ⤷ Get Started Free |
| Poland | 2310411 | ⤷ Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
